Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Baseline Productions, Inc. (BSSP)
San Clemente, CA, US
As of 2021, Baseline Productions, Inc. is actively pursuing opportunities for a merger or acquisition. Simultaneously, the company is working to bring its operations and status up-to-date. This strategic shift follows a significant development on October 9, 2017, when its Pharmaceutical Services Agreement (PSA) with Canteck Pharma, Inc. was terminated. The reason for this termination was the company's inability to secure the necessary licensing to proceed with its immunotherapeutic-based technology, which was specifically targeted at cancer indications, within Mexico.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +19,900.00% | +19,900.00% | +100.00% | +19,900.00% | -83.33% | +0.00% | -99.96% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-133.3% Q3'15: +33.3% (vs Q3'14)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q3'15: -25.4% (vs Q3'14)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q3'15: +32.5% (vs Q3'14)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.38× Q3'15: -3.19× (vs Q3'14)
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Blackbridge Capital, LLC Tax Identification number: 46-1044853 | 120.00M | 9.50% | 120.00M | — | 120.00M | — | CO | Delaware | 2016-05-10 | ↗ |
| 2 | Blackbridge Capital, LLC | — | 0.00% | — | — | — | — | CO | Delaware | 2017-02-16 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dennis R. Alexander | Chairman & Chief Executive Officer | — | male |
| Diana Zhabilov | President | — | — |
| Joanne Sylvanus | Chief Financial Officer, Secretary & Director | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BSSP
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
